We aim to identify novel interventions for prevention and treatment of diabetes-related cardiovascular disease (CVD). Our strategy is to identify genetic, endocrine and metabolic disturbances in humans which are causally related to disease development and are detectable many years before disease presents. We then test in both animals and in human intervention studies if manipulation of such molecular disturbances ameliorate cardiometabolic risk.